These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 7878854)

  • 1. Effects of fialuridine on hepatitis B immune globulin pharmacokinetics following orthotopic liver transplant for chronic hepatitis B viral-induced cirrhosis.
    McGory RW; Ishitani MB; Oliveira WM; Stevenson WC; Dickson RC; Caldwell SH; Pruett TL
    Transplant Proc; 1995 Feb; 27(1):1213-4. PubMed ID: 7878854
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis B immune globulin dose requirements following orthotopic liver transplantation for chronic hepatitis B cirrhosis.
    McGory R; Ishitani M; Oliveira W; Stevenson W; McCullough C; Pruett T
    Transplant Proc; 1996 Jun; 28(3):1687-8. PubMed ID: 8658840
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunoprophylaxis for hepatitis B virus reinfection after liver transplantation.
    Jeng LB; Lee WC; Yeh DS; Wang CC; Wang KL; Chen SC; Chen MF; Chien RN; Chiu CT; Lin DY
    Transplant Proc; 1994 Aug; 26(4):2243-4. PubMed ID: 8066736
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation.
    Ben-Ari Z; Zemel R; Kazetsker A; Fraser G; Tur-Kaspa R
    Am J Gastroenterol; 1999 Mar; 94(3):663-7. PubMed ID: 10086648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allograft biopsies in situ hybridization HBVDNA detection of serum HBs Ag-repositive patients treated with anti-HBV immunoprophylaxis after liver transplantation for HBV cirrhosis.
    Reynès M; Tricottet V; Samuel D; Sebagh M; Bismuth A; Arulnaden J; Brechot C; Bismuth H
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1347-8. PubMed ID: 8442139
    [No Abstract]   [Full Text] [Related]  

  • 6. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
    Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
    J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.
    McKenzie R; Fried MW; Sallie R; Conjeevaram H; Di Bisceglie AM; Park Y; Savarese B; Kleiner D; Tsokos M; Luciano C
    N Engl J Med; 1995 Oct; 333(17):1099-105. PubMed ID: 7565947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dynamics of HBV-DNA level in acute hepatitis B].
    Zhao H; Cao JH; Tian GS
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Jun; 17(2):159-61. PubMed ID: 12870000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful retransplantation for recurrent posttransplant hepatitis B virus infection in the primary allograft.
    Ishitani M; McGory R; Dickson R; Caldwell S; Bickston S; McCullough C; Pruett T
    Transplant Proc; 1996 Jun; 28(3):1714-6. PubMed ID: 8658852
    [No Abstract]   [Full Text] [Related]  

  • 10. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen.
    Petit MA; Buffello-Le Guillou D; Roche B; Dussaix E; Duclos-Vallée JC; Féray C; Samuel D
    J Med Virol; 2001 Nov; 65(3):493-504. PubMed ID: 11596084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of hepatitis B].
    Telegdy L
    Orv Hetil; 2004 Nov; 145(45):2293-6. PubMed ID: 15573894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing infection-associated cancer: from bench to hillside.
    Goedert JJ
    J Natl Cancer Inst; 2005 Feb; 97(4):245-6. PubMed ID: 15713953
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical course of four patients receiving the experimental antiviral agent fialuridine for the treatment of chronic hepatitis B infection.
    Stevenson W; Gaffey M; Ishitani M; McCullough C; Dickson R; Caldwell S; Lobo P; Pruett T
    Transplant Proc; 1995 Feb; 27(1):1219-21. PubMed ID: 7878856
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination hepatitis B immune globulin and lamivudine versus hepatitis B immune globulin monotherapy in preventing recurrent hepatitis B virus infection in liver transplant recipients.
    Ben-Ari Z; Mor E; Bar-Nathan N; Shaharabani E; Shapira Z; Tur-Kaspa R
    Transplant Proc; 2003 Mar; 35(2):609-11. PubMed ID: 12644066
    [No Abstract]   [Full Text] [Related]  

  • 15. Evolution of wild-type and precore mutant HBV infection after liver transplantation.
    Torre F; Wong PY; Macartney M; Williams R; Naoumov NV
    J Med Virol; 1999 Sep; 59(1):5-13. PubMed ID: 10440801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
    Sponseller CA; Bacon BR; Di Bisceglie AM
    Liver Transpl; 2000 Nov; 6(6):715-20. PubMed ID: 11084057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Milan multicenter experience in 96 liver transplants for hepatitis B virus-related cirrhosis.
    Caccamo L; Belli LS; Mazzaferro V; Colledan M; Alberti A; Regalia E; Fassati LR; Ideo G; Rubino A; Belli L
    Transplant Proc; 1994 Dec; 26(6):3585-7. PubMed ID: 7998283
    [No Abstract]   [Full Text] [Related]  

  • 18. [Evaluation of the changes of HBV serum markers and HBV DNA and the effects of perioperative factors after liver transplantation].
    Tang YM; Chen GH; He XS; Zhu XF; Chen MH
    Zhonghua Gan Zang Bing Za Zhi; 2005 Mar; 13(3):164-7. PubMed ID: 15760545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study.
    Ikeda K; Kobayashi M; Someya T; Saitoh S; Hosaka T; Akuta N; Suzuki F; Suzuki Y; Arase Y; Kumada H
    J Viral Hepat; 2009 Jun; 16(6):437-43. PubMed ID: 19226331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection.
    Tennant BC; Baldwin BH; Graham LA; Ascenzi MA; Hornbuckle WE; Rowland PH; Tochkov IA; Yeager AE; Erb HN; Colacino JM; Lopez C; Engelhardt JA; Bowsher RR; Richardson FC; Lewis W; Cote PJ; Korba BE; Gerin JL
    Hepatology; 1998 Jul; 28(1):179-91. PubMed ID: 9657111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.